Indole: A privileged scaffold for the design of anti-cancer agents

被引:361
|
作者
Wan, Yichao [1 ,2 ]
Li, Yuanhua [1 ,2 ]
Yan, Chunxing [1 ,2 ]
Yan, Mi [3 ]
Tang, Zilong [1 ,2 ]
机构
[1] Hunan Univ Sci & Technol, Key Lab Theoret Organ Chem & Funct Mol, Hunan Prov Key Lab Controllable Preparat & Funct, Minist Educ,Sch Chem & Chem Engn, Xiangtan 411201, Hunan, Peoples R China
[2] Hunan Univ Sci & Technol, Hunan Prov Coll, Key Lab QSAR QSPR, Hunan Prov Key Lab Adv Mat New Energy Storage & C, Xiangtan 411201, Hunan, Peoples R China
[3] Shandong Univ, Hosp 2, Dept Pharm, Jinan 250033, Shandong, Peoples R China
基金
中国国家自然科学基金;
关键词
Indole; Drug design; Anti-Cancer; Structure-activity relationships; HISTONE DEACETYLASE INHIBITORS; TUBULIN POLYMERIZATION INHIBITORS; FRAGMENT-BASED METHODS; BIOLOGICAL EVALUATION; MCL-1; INHIBITORS; SELECTIVE INHIBITORS; ANTITUMOR-ACTIVITY; POTENT INHIBITORS; DUAL INHIBITORS; DISCOVERY;
D O I
10.1016/j.ejmech.2019.111691
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
In general, heterocyclic compounds are a significant source of pharmacologically active compounds. Among them, the indole scaffold widely distributes in natural products and bioactive molecules including anti-cancer agents. In view of its unique physic-chemical and biological properties, it has been used as a privileged scaffold in the anti-cancer agents design. So far, many natural and synthetic indole derivatives have been discovered as promising anti-cancer agents used in clinic or clinical evaluations, suggesting its prominent place in anti-cancer drugs development. This review aimed to provide a clear knowledge on the recent development of indoles as anti-cancer agents, such as myeloid cell leukemia-1 (Mcl-1) inhibitors, proviral insertion site in moloney murine leukemia virus (Pim) inhibitors, histone deacetylase (HDAC) inhibitors, silent mating type information regulation 2 homolog (SIRT) inhibitors and tubulin inhibitors, and made an insight into the corresponding structure-activity relationships (SARs). We hope the review could give a guide to develop new anti-cancer agents with greater potency against drug-sensitive and drug-resistant cancers in the future. (C) 2019 Elsevier Masson SAS. All rights reserved.
引用
收藏
页数:18
相关论文
共 50 条
  • [41] Role of Anti-Cancer Peptides as Immunomodulatory Agents: Potential and Design Strategy
    Tripathi, Amit Kumar
    Vishwanatha, Jamboor K.
    PHARMACEUTICS, 2022, 14 (12)
  • [42] NATURAL ANTI-CANCER AGENTS FOUND
    不详
    NEW SCIENTIST, 1985, 105 (1439) : 21 - 21
  • [43] Gold Derivatives as Anti-Cancer Agents
    Rodriguez Raurell, Laura
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2011, 11 (10) : 920 - 920
  • [44] Quassinoids as Promising Anti-cancer Agents
    Mishra, Tripti
    Saima, Bimal Krishna
    Banik, Bimal Krishna
    CURRENT MEDICINAL CHEMISTRY, 2024,
  • [45] THE USE OF HERBS AS ANTI-CANCER AGENTS
    HSU, B
    AMERICAN JOURNAL OF CHINESE MEDICINE, 1980, 8 (04): : 301 - 306
  • [46] ANTI-CANCER AGENTS IN CONDYLOMA ACUMINATUM
    DOLL, DC
    WASSERMAN, PI
    NEW ENGLAND JOURNAL OF MEDICINE, 1979, 301 (23): : 1288 - 1289
  • [47] Bradykinin antagonists as anti-cancer agents
    Stewart, JM
    CURRENT PHARMACEUTICAL DESIGN, 2003, 9 (25) : 2036 - 2042
  • [48] Antibodies and their fragments as anti-cancer agents
    Schaedel, O
    Reiter, Y
    CURRENT PHARMACEUTICAL DESIGN, 2006, 12 (03) : 363 - 378
  • [49] Reengineered tricyclic anti-cancer agents
    Kastrinsky, David B.
    Sangodkar, Jaya
    Zaware, Nilesh
    Izadmehr, Sudeh
    Dhawan, Neil S.
    Narla, Goutham
    Ohlmeyer, Michael
    BIOORGANIC & MEDICINAL CHEMISTRY, 2015, 23 (19) : 6528 - 6534
  • [50] SYNTHESIS OF POTENTIAL ANTI-CANCER AGENTS
    SINGH, NN
    SINGH, B
    SINGH, GP
    SINGH, PN
    PATNA, PU
    HETEROCYCLES, 1984, 21 : 440 - 440